Abacavir/Lamivudine Versus Emtricitabine/Tenofovir Both In Combination With Lopinavir/Ritonavir For The Treatment Of HIV
Completed
GlaxoSmithKline
Phase 4
2005-07-01
This study was designed to test the safety and effectiveness of EPZICOM(abacavir/lamivudine)
and TRUVADA (emtricitabine/tenofovir) for the treatment of HIV infection when both are used
in combination with KALETRA (lopinavir/ritonavir) over 96 weeks
Comparing the Effectiveness Between Ritonavir Boosted Atazanavir and Efavirenz for the First HIV Treatment
Completed
Ministry of Health, Labour and Welfare, Japan
Phase 3
2005-09-01
A selection study in treatment naive HIV patients to compare the virologic success rate of
once daily antiretroviral treatment regimens at the 48th week with Epzicom(lamivudine and
abacavir) plus efavirenz and Epzicom plus ritonavir boosted atazanavir. The superior regimen
will be hired to the comparative study to the current first line regimen (tenofovir plus
lamivudine plus efavirenz)
Comparing the Effectiveness Between Ritonavir Boosted Atazanavir and Efavirenz for the First HIV Treatment
Completed
International Medical Center of Japan
Phase 3
2005-09-01
A selection study in treatment naive HIV patients to compare the virologic success rate of
once daily antiretroviral treatment regimens at the 48th week with Epzicom(lamivudine and
abacavir) plus efavirenz and Epzicom plus ritonavir boosted atazanavir. The superior regimen
will be hired to the comparative study to the current first line regimen (tenofovir plus
lamivudine plus efavirenz)
A Randomized, Prospective Study of the Efficacy, Safety and Tolerability of Two Doses of GW433908Ritonavir Given With Abacavir/Lamivudine Fixed Dose Combination
Completed
GlaxoSmithKline
Phase 4
2006-03-01
The purpose of this study is to evaluate the antiretroviral efficacy, safety, and
tolerability of fos-amprenavir boosted with either of two doses of ritonavir (RTV) when
administered in combination with ABC/3TC (abacavir/lamivudine, Epzicom®) FDC (fixed dose
combination) in a once-daily regimen over 96 weeks in ART-naïve, HIV-infected adults
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
